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Abstract
Background: Because latanoprost and the original formulation of travoprost that included benzalkonium chloride
(BAK) have been shown to be similar with regard to tolerability, we compared initial topical intraocular pressure
(IOP)-lowering medication change rates in patients newly treated with latanoprost or travoprost-Z monotherapy.
Methods: At 14 clinical practice sites, medical records were abstracted for patients with a diagnosis of open-angle
glaucoma or ocular hypertension and who were ≥40 years of age, had a baseline and at least one follow-up visit,
and had no prior history of ocular prostaglandin use. Data regarding demographics, ocular/systemic medical
histories, clinical variables, therapy initiations and reasons for changes, adverse events, and resource utilization were
recorded from randomly chosen eligible charts. Primary outcomes were rates of and reasons for changing from the
initial therapy within six months and across the full study period (1000 days).
Results: Data from 900 medical charts (latanoprost, 632; travoprost-Z, 268) were included. For both cohorts,
average follow-up was >1 year. Cohorts were similar with regard to age (median ~67 years), gender distribution
(>50% female), and diagnosis (~80% with open-angle glaucoma). Within six months, rates of index therapy change
for latanoprost versus travoprost-Z were 21.2% (134/632) and 28.7% (77/268), respectively (p = 0.0148); across the
full study period, rates were 34.5% (218/632) and 45.2% (121/268), respectively (p = 0.0026). Among those who
changed their index therapy, insufficient IOP control was the most commonly reported reason followed by adverse
events; hyperemia was the most commonly reported adverse event at index therapy change.
Conclusions: In this “real world” study of changes in therapy in patients prescribed initial monotherapy with
latanoprost with BAK or travoprost-Z with SofZia, medication changes were common in both treatment groups but
statistically significantly more frequent with travoprost-Z.
Background
Research has demonstrated that progression of ocular
hypertension to glaucoma and progression of glaucoma-
tous damage can be delayed or halted with the use of
topical ocular hypotensive agents [1-4]. Patients can ben-
efit from these therapies only if they are taken as directed
over the long term; however, medication discontinuation
and changes may complicate patient management and
make intraocular pressure (IOP) control problematic.
Unfortunately, persistence with ocular hypotensives gen-
erally has been shown to be poor [5-11] although better
with prostaglandin analogs than with agents in other
classes [5,7,8,12]. Therapeutic interruptions may occur
for many reasons. In patients treated with latanoprost,
travoprost, or bimatoprost, the Glaucoma Adherence and
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additional IOP reduction and the presence of ocular
adverse events, especially hyperemia, to be the main fac-
tors affecting continuation with therapy and medication
changes.
All three prostaglandins evaluated in the GAPS [11]
were preserved with benzalkonium chloride (BAK). Cur-
rently the most widely used preservative in ocular hypo-
tensive formulations, BAK has been in use for more than
50 years [13,14]. While it has been suggested that preser-
vative-free formulations could improve ocular tolerability
and thereby reduce treatment discontinuation [15], such
formulations pose their own risks because preservatives
are added to multiple-use containers of ophthalmic pre-
parations in order to prevent bacterial contamination
[16] and to reduce the risk of serious infections such as
infectious keratitis [14]. Moreover, the contribution of
BAK to ocular toxicity remains unclear. While animal
studies [17-20] and studies of cultured corneal [21] and
conjunctival cells [22] have reported dose-dependent,
BAK-induced epithelial cellular damage, these findings
may not accurately reflect ocular surface conditions in
humans, and the levels of BAK contained in ophthalmic
solutions are not likely to cause clinically significant
adverse corneal effects [23-27].
An alternative preservative, SofZia
®, currently is used
as the preservative in travoprost-Z. Although latanoprost
with BAK has been found to exhibit more effective
microbial protection than travoprost-Z [28], the question
of whether SofZia improves tolerability has not been
resolved. For example, a randomized, double-masked
comparison of travoprost with BAK versus travoprost-Z
found the formulations were equivalent with regard to
tolerability and the occurrence of ocular adverse events
[29], and a comparison of the ocular surface tolerability
of latanoprost and bimatoprost preserved with BAK ver-
sus travoprost-Z found no significant differences in
objective clinical measures of ocular tolerability [30]. In
contrast, results of an in vitro study of corneal epithelial
cells suggested that SofZia may be less toxic than BAK
[31].
Because latanoprost and the original formulation of
travoprost that included BAK have been shown to be
similar with regard to tolerability [32,33], we compared
rates of therapy change in patients with open-angle
glaucoma or ocular hypertension who were newly trea-
ted with latanoprost or travoprost-Z as monotherapy.
Methods
This retrospective multicenter, medical chart review was
conducted at 14 geographically diverse sites in the Uni-
ted States. Prior to including a site, a Pfizer Regional
Medical & Research Specialist conducted an on-site
investigator meeting to review the study protocol and
chart review instructions with the investigator and the
research coordinators/technicians responsible for chart
selection and data abstraction. Training was provided,
and coordinators/technicians abstracted a standardized
dummy chart to ensure consistent and accurate data
collection and documentation. Additional training was
provided as needed to ensure consistency between sites.
Because this was a retrospective study, it did not require
approval from an ethics committee. Each research site
de-identified data on case report forms using numeric
codes to assure patient confidentiality.
Records for patients initiating either latanoprost or tra-
voprost-Z monotherapy for the treatment of bilateral pri-
mary open-angle glaucoma or ocular hypertension
between October 1, 2006, and September 8, 2009, were
reviewed. Eligible patients were ≥40 years of age, had no
prior history of ocular prostaglandin use and had charted
data reflecting at least one follow-up visit during the six
months following the baseline (treatment initiation) visit.
Exclusion criteria included prescription of any ocular
hypotensive medication in the six months prior to the
baseline visit; concomitant diagnosis of closed-angle glau-
coma; participation in an ophthalmology-related clinical
trial in the three months prior to baseline; intraocular sur-
gery prior to baseline; and the existence of any clinical
condition that would contribute to discontinuation (e.g.
ocular infection, allergy).
Each site was asked to randomly choose an alphabetical
starting point and, beginning with October 1, 2006, to
identify consecutive charts that met all inclusion and no
exclusion criteria. Sites were to review consecutive charts
until records for 60 patients who initiated latanoprost
monotherapy and 30 who initiated travoprost-Z mono-
therapy were identified. The unbalanced sample size
reflected the fact that travoprost-Z was introduced only in
2006 and was prescribed less frequently than latanoprost
which has been available since 1996. Once the target num-
ber for one therapy cohort was reached, the site was to
continue to select consecutive eligible charts for the
remaining cohort only. The smallest site contributed 20
patients and the largest site contributed 92 patients.
Demographic data (age, gender) were recorded. For
baseline and all follow-up visits, the visit date; diagnosis;
IOP level; visual field defect; cup-to-disc ratio; central
corneal thickness; and ocular comorbidities, diagnostic
tests, and medications were documented. All reported
adverse events were recorded. An adverse event was
classified as “serious” if it was life-threatening, required
inpatient hospitalization/prolongation of hospitalization,
resulted in persistent or significant disability/incapacity,
or caused congenital anomaly/birth defect or death.
Data were collected from baseline until the end of the
observation period (i.e. last visit) in the charts. The time to
index therapy change was analyzed at month 6 (180 days)
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chart). Research coordinators/technicians responsible for
chart selection and data abstraction were specifically
instructed to exclude patients with disruption in therapy
due to forced formulary changes (switches) during the fol-
low-up period. Patients with changes due to other access
or cost issues, such as those with prescription coverage
who requested less expensive generic products, were
included; for example, higher copays for branded versus
generic drugs.
The statistical significance of between-cohort differ-
ences in categorical variables was tested using the chi-
square test and in continuous variables using the two-
sample t-test. All tests were two-tailed with a signifi-
cance level of p < 0.05.
Change in the index therapy could reflect any of the fol-
lowing: (1) add-on: prescription for an ocular hypotensive
agent in addition to the initial monotherapy; (2) switch:
switch from the index monotherapy to another ocular
hypotensive agent; (3) discontinuation: discontinuation of
ocular hypotensive therapy; and (4) surgery/procedure:
documentation of a glaucoma-related surgery or proce-
dure. Unadjusted Cox proportional hazards models were
used to estimate the hazard of index therapy change
between treatment cohorts from baseline to month six and
from baseline to the end of the study. Kaplan-Meier survi-
val curves graphically represented the probability of chan-
ging the index therapy throughout the follow-up periods.
Based on results of the GAPS [11] and assuming that
travoprost and travoprost-Z have similar tolerability pro-
files, a sample of 659 charts of latanoprost-treated
patients and 329 charts of those treated with travoprost-
Z was estimated to provide an 80% power to demon-
strate a meaningful difference between latanoprost (4.2%
change rate) and travoprost-Z (9.0% change rate) at a
0.05 significance level.
Results
In all, charts for 632 patients initiating monotherapy with
latanoprost and for 268 treated initially with travoprost-Z
monotherapy were abstracted. Baseline demographic char-
acteristics and medical histories are summarized in Table 1.
In both cohorts, the median age was approximately 67
years, >50% were female, and 80% were diagnosed with pri-
mary open-angle glaucoma. Systemic comorbidities at base-
line were common with more than half of the patients in
each cohort reporting hypertension and approximately
one-quarter reporting a lipid disorder. At baseline, nearly
30% in each cohort had undergone cataract surgery, and
approximately 10% reported a history of dry eye. Baseline
IOP values were similar across treatment groups in both
eyes.
Ocular procedures and ocular surface tests were per-
formed with similar frequency across cohorts at the
baseline visit (Table 2). As would be expected, records
for virtually all patients included a notation of IOP level,
while results of perimetry, ophthalmoscopy, gonioscopy,
and measurement of central corneal thickness were
recorded for approximately half of the patients overall.
At baseline, ocular surface tests were performed rela-
tively infrequently in both cohorts. Over the full study
period, the mean ± standard deviation number of office
visits was 3.9 ± 2.3 for latanoprost and 4.1 ± 2.7 for
Table 1 Baseline demographic characteristics and
medical history*
Latanoprost
N = 632
Travoprost-Z
N = 268
Age, years
Mean ± SD 66.7 ± 12.8 66.9 ± 11.1
Median (range) 67.0 (32, 97) 66.5 (42, 96)
Gender
Male 284 (45.0) 126 (47.6)
Female 347 (55.0) 139 (52.5)
Diagnosis
Primary open-angle glaucoma 499 (80.0) 214 (79.9)
Ocular hypertension 119 (19.3) 52 (19.5)
Family history of glaucoma
Yes 131 (20.7) 65 (24.3)
No 501 (79.3) 203 (75.8)
Systemic comorbidities
†
Hypertension
‡ 322 (51.0) 159 (59.3)
Lipid disorder 170 (26.9) 60 (22.4)
Diabetes
‡ 108 (17.1) 65 (24.3)
Thyroid disease 76 (12.0) 24 (9.0)
Allergic rhinitis 50 (7.9) 17 (6.3)
Asthma 40 (6.3) 19 (7.1)
Depression 39 (6.2) 12 (4.5)
Other 310 (49.1) 121 (45.2)
Coexisting ocular conditions
†
Cataract surgery 173 (27.4) 80 (29.9)
Dry eye 83 (13.1) 27 (10.1)
Macular degeneration 42 (6.7) 13 (4.9)
Diabetic retinopathy 17 (2.7) 9 (3.4)
Seasonal allergic conjunctivitis 7 (1.1) 6 (2.2)
Other 319 (50.5) 154 (57.5)
Intraocular pressure
§
Right eye
Mean ± SD 22.9 ± 6.2 23.1 ± 6.7
Median 22 22
Left eye
Mean ± SD 22.4 ± 5.4 22.5 ± 5.5
Median 22 22
SD = standard deviation.
*N (%) unless otherwise indicated.
†Reported by ≥2% of patients in either cohort.
‡p < 0.05.
§Latanoprost, N = 629; travoprost-X, N = 267.
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was similar between cohorts (latanoprost: 405.7 ± 257.5
days, range 5 to 1034 days; travoprost-Z: 397.8 ± 248.2
days, range 8 to 1000 days).
Within six months, rates of index therapy change for
latanoprost versus travoprost-Z were 21.2% (134/632)
and 28.7% (77/268), respectively (p = 0.0148); across the
full study period, rates were 34.5% (218/632) and 45.2%
(121/268), respectively (p = 0.0026; Table 3). Patients
initially treated with travoprost-Z were 52% more likely
(hazard ratio [HR]: 1.52; 95% confidence interval
[CI]:1.15-2.00; p = 0.0035) to have an index therapy
change within the first six months and 50% more likely
(HR: 1.50; 95% CI: 1.20-1.87; p = 0.0004) to experience
an index therapy change during the study compared
with patients treated first with latanoprost. Among
those changing therapy, days to therapy change was
longer among those initially treated with latanoprost.
The time in days to index therapy change are shown in
Kaplan-Meier curves for the two ocular hypotensive
therapies in Figures 1 and 2.
Among those who changed their index therapy, switch
to a different ocular hypotensive agent was the most fre-
q u e n tt y p eo fc h a n g ei nb o t ht i m ep e r i o d s( > 4 0 %o f
changes), followed by the addition of ocular hypotensive
therapy (>26% of changes; Table 4). The most frequently
cited reason for change was insufficient IOP control
reported for >60% of those changing therapy within the
first six months and for >50% of those changing across
the full study period (Table 4; patients with therapy dis-
ruption related to access or formulary changes were
excluded from chart abstraction). The second most fre-
quently cited reason was the occurrence of adverse
events. Hyperemia was the adverse advent charted most
frequently at the time of the first index therapy change
in both measurement time periods and was reported
approximately four times more frequently among those
treated with travoprost-Z (p < 0.0001 for both within six
months and across the full study period; Table 5). Dry
eye was reported infrequently, in 1/134 patients in the
latanoprost group and 1/77 patients in the travoprost-Z
group, and was not reported as a reason for withdrawal
by any patient. When those who switched therapy due
to insufficient IOP control were excluded, time to index
therapy change was longer among those treated initially
with latanoprost during both the first six months and
the full study period (p = 0.0523 and p = 0.0427,
respectively).
Discussion
Although we hypothesized that the rate of index therapy
change would be lower with travoprost-Z preserved with
SofZia than with latanoprost preserved with BAK, we
found change rates to be statistically significantly lower
in latanoprost-treated patients both within six months
and across the full study period. As in studies of persis-
tency with ocular hypotensive agents generally, rates of
uninterrupted use were lower than desirable for both
Table 2 Ocular procedures and ocular surface tests
performed at baseline, N (%)*
Latanoprost
N = 632
Travoprost-Z
N = 268
Ocular procedures
IOP 627 (99.2) 265 (98.9)
Perimetry 344 (54.4) 132 (49.3)
Ophthalmoscopy 330 (52.2) 143 (53.4)
Gonioscopy 303 (47.9) 147 (54.9)
Central corneal thickness measured
† 280 (44.3) 144 (53.7)
Photography
† 130 (20.6) 33 (12.3)
Heidelberg retinal tomography 154 (24.4) 55 (20.5)
Optical coherence tomography 97 (15.4) 55 (20.5)
GDx nerve fiber analysis 31 (4.9) 16 (6.0)
Ocular surface tests
Tear breakup time 57 (9.0) 28 (10.5)
Staining 13 (2.1) 4 (1.5)
*Reported by ≥2% of patients in either cohort.
†p < 0.05.
Table 3 Index therapy change within 6 months and full study period
Within 6 months Across full study period
Latanoprost
N = 632
Travoprost-Z
N = 268
Latanoprost
N = 632
Travoprost-Z
N = 268
Changed therapy, n % 134 (21.2) 77 (28.7) 218 (34.5) 121 (45.2)
p-value* 0.0148 0.0026
Hazard ratio
† 1.519 1.499
p-value 0.0035 0.0004
Days to change
Mean ± SD 72.9 ± 51.2 54.1 ± 48.0 194.8 ± 192.9 178.0 ± 196.7
Median 56.5 40.0 125.0 90.0
SD = standard deviation.
*Chi-square test.
†The reference cohort is latanoprost. Based on the Cox proportional hazards model.
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scribed travoprost-Z were approximately 50% more likely
to change therapy both within the first 6 months and
across the full study period (p < 0.01 for both compari-
sons with latanoprost). Combining proportions of
patients who either switched or discontinued to estimate
how many patients completely stopped taking the initial
therapy revealed that, within the first six months, 12.5%
(79/632) of latanoprost-treated patients and 15.3% (41/
268) of those treated with travoprost-Z stopped the initial
therapy and that 19.8% (125/632) and 23.5% (63/268),
respectively, did so across the full study period. Similar
proportions of patients in the two treatment groups
changed due to a glaucoma-related surgery or procedure
(approximately 14% at each measurement time point).
Our finding of greater persistence with latanoprost
monotherapy than with travoprost-Z monotherapy
contrasts with results of retrospective claims database
analyses of prostaglandin analog treatment patterns
[34-36]. In those studies, rates of adjunctive IOP-lower-
ing therapy use favored travoprost-Z, with differences
between latanoprost and travoprost-Z ranging from
7.6% over 12 months (16.5% vs 8.9%, respectively) [34]
to 2% over two years (37% vs 35%, respectively) [35].
Directly comparing findings of the present study and
the published claims database analyses is difficult given
differences in research questions, definitions of out-
comes, and statistical analyses. In particular, the studies
by Schmier et al [34-36] included only newly initiating
patients who remained on the index prostaglandin for
least 12 or 24 months (depending on the study), while
the present research identified patients newly prescribed
an ocular prostaglandin and tracked therapy changes
throughout the follow-up period. Nevertheless, such
contrasting results suggest that additional research is
needed to evaluate whether the low levels of BAK con-
tained in ophthalmic solutions may cause significant
adverse corneal effects that impact patient persistence.
Changes in ocular hypotensive therapy may be preci-
pitated by a number of factors. In the GAPS [11] with
an average duration of chart review of 4.1 years, lack of
efficacy was the most common reason cited by physi-
cians for switching medication followed by adverse
events (43% vs 19%, respectively). Among patients who
changed therapy in the present study, uncontrolled IOP
was noted as a reason for change within the first six
months in >60% charts and as a reason for nearly 55%
of changes from latanoprost and 63% of changes from
travoprost-Z across the full study period. As in the
GAPS [11], adverse events were the second most fre-
quently cited reason for change, noted in between 11%
and 21% of cases; changes were attributed to adverse
events in somewhat greater proportions of those treated
with travoprost-Z.
The most frequently recorded adverse event was hyper-
emia, which was noted significantly more frequently with
travoprost-Z than with latanoprost at both measurement
time points. In the GAPS [11], hyperemia also was the
most common adverse event. In that study, of the 195
patients with charted adverse events, hyperemia was
noted in 135 (69%) records, and an episode of hyperemia
occurred in a significantly greater proportion of those
exposed to travoprost (35%) than to latanoprost (22%; p
= 0.0123). It has been suggested that BAK exposure is
related to an increased incidence of dry eye [15], but
therapy withdrawals from dry eye were not obvious in
the latanoprost with BAK group.. This lack of association
between these agents and the incidence of dry eye paral-
lel the results of a retrospective analysis of three large
prescription databases that found no significant differ-
ence in the incidence of ocular surface disease (defined
Figure 1 Kaplan-Meier curves of days to index therapy change
within 6 months.
Figure 2 Kaplan-Meier curves of days to index therapy change
across the full study period.
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scribed latanoprost versus travoprost-Z (14.0% vs 14.4%,
respectively; p = 0.45) [37].
The American Academy of Ophthalmology [38,39]
and the European Glaucoma Society [40] have produced
guidelines for the evaluation and treatment of patients
with glaucoma or ocular hypertension, but eye care pro-
fessionals may not routinely follow these recommenda-
tions [41-44]. In the GAPS [44], IOP and results of disc
evaluations and imaging and of visual field tests were
recorded in charts of 90% of open-angle glaucoma
patients; in contrast, chart notations of central corneal
thickness measurement, gonioscopy, and establishment
of an IOP target level were present for about half of
patients. In the present study, we tabulated frequencies
of ocular procedures and ocular surface tests performed
at baseline. An IOP measurement was recorded for
nearly all (>98%) patients in both treatment groups and
about half of charts included findings of perimetry,
ophthalmoscopy, gonioscopy, and central corneal thick-
ness measurement. Other procedures and ocular surface
tests were performed less frequently.
Am a j o rs t r e n g t ho ft h ec u r r e n ts t u d yw a st h el a r g e
number of charts reviewed (N = 900). However, the fol-
low-up time frame was too short to support assessments
of changes in parameters such as visual field. Rates of ther-
apy “gaps” and restarts, which have been documented
using large medical/pharmacy databases [10,11], cannot be
reliably inferred from medical records. Although the 14
sites from which data were abstracted were geographically
Table 4 Type of and reason for index therapy change within 6 months and full study period among patients who
changed, N (%)
Within 6 months Across full study period
Latanoprost
N = 134
Travoprost-Z
N=7 7
Latanoprost
N = 218
Travoprost-Z
N = 121
Type of change
Add-on 36 (26.9) 26 (33.8) 62 (28.4) 40 (33.1)
Switch 65 (48.5) 36 (46.8) 102 (46.8) 50 (41.3)
Discontinuation 14 (10.5) 5 (6.5) 23 (10.6) 13 (10.7)
Surgery/procedure 19 (14.2) 10 (13.0) 31 (14.2) 18 (14.9)
Reason for change*
IOP not controlled 83 (61.9) 50 (64.9) 119 (54.6) 76 (62.8)
Adverse events 16 (11.9) 16 (20.8) 24 (11.0) 18 (14.9)
Physician preference 11 (8.2) 4 (5.2) 21 (9.6) 9 (7.4)
Non-compliance 8 (6.0) 2 (2.6) 11 (5.0) 6 (5.0)
Cost 9 (6.7) 3 (3.9) 19 (8.7) 4 (3.3)
Patient request 5 (3.7) 2 (2.6) 10 (4.6) 4 (3.3)
Ocular nerve head
changes 1 (0.7) 0 6 (2.8) 1 (0.8)
Other 11 (8.2) 3 (3.9) 25 (11.5) 5 (4.1)
IOP = intraocular pressure.
*Reported by ≥2% of patients in either cohort at either time point. More than one reason could be reported for each patient.
Table 5 Adverse event(s) charted at index therapy change within 6 months and full study period among patients who
changed, N (%)
Within 6 months Across full study period
Latanoprost
N = 134
Travoprost-Z
N=7 7
Latanoprost
N = 218
Travoprost-Z
N = 121
Hyperemia
† 7 (5.2) 18 (23.4) 10 (4.6) 21 (17.4)
Burning 7 (5.2) 2 (2.6) 10 (4.6) 2 (1.7)
Pain/ocular discomfort 4 (3.0) 3 (3.9) 4 (1.8) 4 (3.3)
Blepharitis 3 (2.2) 2 (2.6) 4 (1.8) 2 (1.7)
Dry eye 1 (0.7) 1 (1.3) 3 (1.4) 4 (3.3)
Foreign body sensation 1 (0.7) 2 (2.6) 2 (0.9) 4 (3.3)
Pruritis 1 (0.7) 0 7 (3.2) 1 (0.8)
Other 8 (6.0) 8 (10.4) 16 (7.3) 10 (8.3)
*Reported by ≥2% of patients in either cohort at either time point. More than one event could be reported for each patient.
†p < 0.0001 for both within six months and across full study period.
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ophthalmology practices. Every effort was made to ensure
the consistency of chart abstraction across sites, but no
formal tests of reliability were undertaken. In addition,
time to and reasons for changing medication were not
cross-validated by an independent committee and were
not evaluated in a masked fashion. Insufficient IOP reduc-
tion was the most commonly reported reason for change,
but IOP changes at the patient level were not assessed and
could be considered in future analyses. Finally, because
latanoprost and the original formulation of travoprost
with BAK have similar tolerability profiles [32,33], we
hypothesized that any improvement in the tolerability of
travoprost with SofZia would lead to lower rates of ther-
apy change in comparison to latanoprost with BAK.
Although we did not find lower rates of therapy change
among those treated with travoprost-Z, future research
might expand the study by comparing persistence with
BAK-preserved travoprost, bimatoprost, and latanoprost
versus ocular hypotensive formulations without BAK -
including travoprost with SofZia
Conclusion
In this “real world” study of changes in therapy in
patients prescribed initial monotherapy with latanoprost
with BAK or travoprost-Z with SofZia, medication
changes were common in both treatment groups but sta-
tistically significantly more frequent with travoprost-Z.
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